BA401 EliLilly and Company Drug Development Strategy
Upcoming SlideShare
Loading in...5
×
 

BA401 EliLilly and Company Drug Development Strategy

on

  • 1,144 views

 

Statistics

Views

Total Views
1,144
Views on SlideShare
1,144
Embed Views
0

Actions

Likes
1
Downloads
39
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

BA401 EliLilly and Company Drug Development Strategy BA401 EliLilly and Company Drug Development Strategy Presentation Transcript

  • Eli Lilly and Company
    :Drug Development Strategy (A)
  • Introduction to
    the Pharmaceutical Industry
    In the mid 1990s
  • By the mid 1990s, annual worldwide pharmaceutical
    sales were around $250 billion, with roughly 80 percent
    originating in the industrialized G7 nations.
    Top Blockbuster drugs targeted diseases of particular
    concern to industrialized nations.
  • U.S. Pharmaceutical Market
    by Therapeutic Category (1994)
  • Summary of Drug Development
    in the USA
  • Under current law, a patent’s term expired
    20 years from the time the patent application
    was field (prior to 1995, patent protection
    extended 17 years after the patent was issued.)
    Sales of only a few products could provide
    exceptional returns. In the mid 1990s,
    14 products had annual sale over $1 billion,
    enabling profit margins of 15-20 percent.
  • Top 20 Prescription Drugs by
    Worldwide Sales (1994)
    (dollar in millions)
  • Top 20 Firms Active in the
    Pharmaceutical Industry (1994)
    (dollars in millions)
  • Eli Lilly and Company
  • Eli Lilly and Company was
    found In Indianapolis, Indiana
    in 1876 by Colonel Eli Lilly.
    In the mid 1990s, Lilly,
    operating in 150 countries,
    was one of the world’s largest pharmaceutical
    company, with over
    25,000 employees and
    1994 sales of $5.7 billion.
  • Eli Lilly and Company
    - Organization Chart
  • Chairman and CEO
    R. L. Tobias
    A. M. Watanabe, MD
    Executive VP Science &
    Technology
    VP, Human
    Resources
    Executive VP,
    Finance & CFO
    VP & General
    Counsel
    President
    & COO
    VP,
    Cardiovascular
    Eisenstein, MD
    VP Technology Core &
    Infectious Disease
    VP,
    Regulatory Affairs
    CNS Business
    Unit
    VP,
    Endocrinology
    VP,
    Development
    M. Haslanger, PhD
    Executive Director,
    Research Technology
    And Proteins,
    President, Sphinx
    Pharmadeuticals
    VP,
    Cancer
    VP, Medical
    (Phases II & III)
    VP, Central
    Nervous System
    Bianca Sharma,
    Project Manager
    S. Kaldor, PhD, Head of
    Combinatorial Chemistry
    J. Schaus, PhD, Senior
    Research Scientist
  • Eli Lilly and Company
    • 1994 Financial Highlights
    (dollars in million)
  • Eli Lilly and Company
    • Major Product Sales
    (dollars in million)
  • Innovation in the new Drug
    Development Process
  • Combinatorial Chemistry
    At Lilly
  • Combinatorial chemistry is an emerging
    technology for generating a large collection
    or “library” of related chemical compounds
    rapidly, instead of having to make one
    compound at a time. This allows for creating
    variations around the backbone of a basic
    molecular structure.
  • Combinatorial Chemistry
    (the “Split-and-Mix” Method)
  • Central Nervous System
    (CNS) Diseases
  • CNS Diseases accounted for roughly
    10 percent of all lifetime years lost to disease.
    E.g. clinical depression, severe insomnia
    (sleeplessness), and migraine
    Each of which affected over 10 percent
    of the population – could take a severe toll on
    society. For instance, depression might
    predispose people to suicide
  • Lilly’s Migraine Project
  • “Migraine”
    • was characterized by unilateral pulsating
    headaches often severe enough to restrict
    physical and mental activity
    • afflicted 12 percent of population,
    with a 3:1 preponderance in women
  • Imitrex,
    • launched in 1992
    • was a mildly effective drug that act by
    constricting blood vessels
    • had an adverse effect on the heart’s vessels
    Many scientists felt that the makers of
    Imitrex had followed the wrong path by
    trying to find a compound that constricted
    blood vessels(known as “vasoconstriction”).
  • By March 1994, out of over 1,000
    previously synthesized serotonin-like
    compounds one particularly good “lead”
    had been found. In addition, Lilly’s experiments
    in which lab animals were administered these
    lead compounds further promise of the “1f”
    serotonin receptors as treatment targets for
    migraine without the need for inducing
    vasoconstriction.
  • Timeline
  • Difficult choices:
    The Project Team Advisory
    Committee(PTAC) Meeting
  • The three key business
    issues for PTAC Presentation
  • Member of the group
    วริษฐา ภิรมย์รัตน์ 4902680521
    ณัฐกานต์ มีสัตย์ 4902682055
    อัจฉรา บัญชากร 5002686094
    หฤษฎ์ พรรณพานิช 5002686185